Roche PD-L1 of "medical fast reading society" is approved to treat small cell lung cancer in China

As of 24:00 on February 12, 59804 cases have been confirmed in China; 4 senior managers of Sanofi's restructuring management structure have left their jobs; Kelun pharmaceutical has started research work related to radcivir; Roche PD-L1 has been approved to treat small cell lung cancer in China; Pfizer's new drug revanto has been approved As of 24:00 on February 12, 52526 confirmed cases have been reported by provinces, cities and Xinjiang production and Construction Corps Among them, 8030 were serious cases, 5911 were cured and 1367 died There are 59804 confirmed cases, 13435 suspected cases, 471531 close contacts and 181386 close contacts under medical observation (CCTV News) The day before Qiang's birthday, Yang Sen pharmaceutical and the biomedical advanced research and development administration under the U.S Department of health and human services expanded cooperation to further accelerate its research-based coronavirus vaccine project (Sina Medical News) The novel coronavirus vaccine novel coronavirus vaccine was signed jointly by the Tianyuan bio company and the National Key Laboratory of infectious diseases diagnosis (Zhejiang University), 12, the company announced The director of the laboratory is Academician Li Lanjuan In order to ensure the smooth implementation of the project, Tianyuan biology promised to provide special funds for the project within 100 million yuan according to the R & D Progress of the cooperative project (Sina Medical News) On the interactive platform, Kelun pharmaceutical said that on the day when the literature disclosed that radcivir had potential anti crown effect, the Kelun Pharmaceutical Research Institute set up the project and immediately started relevant research work At present, the process development and scale-up research are pushing forward with all strength, and the progress is smooth, and the samples that can be mass produced will be obtained quickly Major progress will be announced in time (AP) According to Bloomberg news, Paul Hudson, CEO of Sanofi, announced that the company's management will be reorganized, and four executives will leave, including Ameet nathwani, medical and digital officer, Dieter weinand, head of primary health care business, Dominique Carouge, head of business transformation, and Kathleen trenging, head of foreign affairs It is not known whether "separation" means immediate effect or elimination within a period of time (Sina Medical News) Hutchison Whampoa pharmaceutical has announced the appointment of he Lijing as Hutchison Whampoa pharmaceutical's senior vice president and chief medical officer, China's clinical and registration director, and reported to Su Weiguo, chief scientific officer and R & D director of Hutchison China Pharmaceutical Technology, effective February 11 (medical representative) On March 12, Pfizer PBG announced the appointment of Huang Canrong as the national sales leader of the new inflammation and immunization team, reporting directly to Wu Kun, chief operating officer of Pfizer PBG in China, effective March 1 (medical representative) On November 11, Yuheng pharmaceutical replied to the inquiry letter of Shenzhen Stock Exchange In 2019, it is estimated that the annual net profit attributable to shareholders of listed companies will be RMB 2.4 billion to 2.6 billion The decline in operating performance is related to the impact of key monitoring catalogue and new version of medical insurance catalogue on related products of wholly-owned subsidiaries Shanghai Huatuo and Nanjing Wanchuan and Pude pharmaceutical (medicine cube) Today, Alex Oncology (formerly alexo therapeutics) announced the completion of a $105 million round C financing to support the phase 2 clinical development of its CD47 checkpoint inhibitor, alx148, in combination with other anticancer therapies for solid and blood cancers (chuangjianhui) On December 12, the application for listing of tecentriq was approved by the State Food and Drug Administration for the treatment of small cell lung cancer The State Food and drug administration has issued approval documents This is the second PD-L1 McAb approved for listing in China after imfinzi of AstraZeneca (medicine cube) On December 12, mosadon announced that its PD-1 inhibitor keytruda (pembrolizumab) combined with chemotherapy reached the primary end point of progression free survival (PFS) in the key phase 3 keynote-355 study for the first-line treatment of metastatic triple negative breast cancer patients (mtnbc) with tumor expression of PD-L1 (combined positive score [CPS] ≥ 10) (Sina Medical News) Roche recently released the Chinese cohort data of the phase III imbrave150 study at the 2020 hepatoma summit This is an open label, multicenter, randomized phase III study in patients with unresectable HCC who have not previously received systematic treatment to investigate the efficacy and safety of the combination of tecentriq and Avastin in the treatment of PD-L1 as compared with the standard care drug, sorafenib, a multi kinase inhibitor (Biovalley) On February 12, Pfizer announced that sildenafil (sildenafil citrate) had been approved by the State Food and Drug Administration of China for the treatment of adult pulmonary hypertension (PAH, who group 1) on February 5, 2020, in order to improve exercise ability and delay clinical deterioration, becoming the first type 5 phosphodiesterase (PDE-5) inhibitor approved for the treatment of pulmonary hypertension in China (Sina Medical News) On December 12, Junshi registered and launched a phase I clinical study of its own developed humanized anti-PD-L1 monoclonal antibody js003 to evaluate the safety, tolerability and dose limiting toxicity (DLT) of js003 in patients with advanced or recurrent solid tumors 36 people are planned to join the group (medicine cube) On October 10, Qilu pharmaceutical capecitabine tablets (0.5g, 0.15g) passed the consistency evaluation and became the first in China Capecitabine is an anti-tumor drug, which is suitable for adjuvant chemotherapy of colon cancer It is mainly used in Dukes' C stage, after radical resection of primary tumor, and single drug adjuvant therapy of colon cancer patients who are suitable for fluoropyrimidine alone (medicine cube) 13, the novel coronavirus pneumonia was launched by the team of Professor Hu Peng of Second Hospital Affiliated to Chongqing Medical University ASC09 composite tablets and alpha interferon atomization treatment of new coronavirus pneumonia were approved by the ethics committee (Sina Medical News)